LakePharma Announces Dedicated Vector Center to Support Gene and Cell TherapyAdded On: 2019-02-26
LakePharma Announces its GMP Biorepository Facility near Boston is Now Operational, Plans Additional HiringAdded On: 2019-01-15
LakePharma announces its cGMP microBiomanufacturing Center is now operationalAdded On: 2018-12-18
Added On: 2017-10-04
LakePharma, the leading US-based biologics company offering integrated solutions for biologics discovery, development and manufacturing, today announced a non-exclusive license agreement with XOMA to use XOMA’s 031 Fab Phage Display Library in its antibody discovery service to pharma and therapeutic biotech companies.
XOMA 031 is a naïve human Fab phage display library with more than 300 billion clones covering the human antibody repertoire. Due to the high sequence diversity of target-specific antibody binders derived from this phage library, high affinity clones can be discovered for many targets. XOMA and its partners have used this library to discover several antibodies that are currently in the clinic.
Aaron Sato, Ph. D., Chief Scientific Officer of LakePharma, said: “The XOMA phage display libraries have yielded many developable, low immunogenicity, and highly potent antibody drug candidates that are currently in the clinic. For these reasons, their library is validated to produce clinical candidates. We are so excited to be able to offer XOMA 031 Fab library discovery projects to our clients.”
LakePharma is the leading US-based biologics company specializing in antibody engineering, antibody discovery, molecular engineering, protein chemistry, bioexpression, biofunction, bioprocessing, and bioanalytics. LakePharma focuses on integrated platforms to support projects throughout the drug discovery process. LakePharma offers dedicated client services and sophisticated software to provide real-time access to project data via a secure cloud-based portal. For more information, please visit lakepharma.com
Aaron Sato, Ph.D.
Chief Scientific Officer, LakePharma
XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the Company has in place with other biotech and pharmaceutical companies. Many of these licenses are the result of the Company's pioneering efforts in the discovery and development of antibody therapeutics. There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. For more information, please visit www.xoma.com.